Learn how Shilpa Medicare grew from a single-site API manufacturer in Raichur to an integrated pharmaceutical partner for global markets.
Founded in 1987 in Raichur, Karnataka, Shilpa Medicare began with a simple belief: quality medicines should be accessible and affordable. What started as a focused API manufacturing unit has evolved into one of India’s most respected pharmaceutical companies with capabilities across APIs, formulations, oncology products and biologics.innovation, dedication, and unwavering commitment to improving human health.
Established with the core belief that quality healthcare should be accessible to all, Shilpa Medicare began its journey with a focus on developing affordable yet high-quality pharmaceutical solutions for the Indian market and beyond.
From day one, our mission has been to develop, manufacture and deliver pharmaceutical products that improve patients’ lives while meeting the highest standards of quality, safety and efficacy. This mission continues to guide every decision as we expand into new technologies, therapies and markets.
Over the decades, Shilpa has steadily built a differentiated portfolio with strengths in complex generics, oncology, biologics and novel drug delivery systems. Our R&D and manufacturing investments are focused on high-impact, difficult-to-make products where we can add meaningful value for patients and partners.
Leadership in affordable generics and specialty APIs, backed by strong process chemistry and regulatory expertise.
Growing presence in biosimilars, biologics and advanced delivery platforms.
Four world-class R&D centers across India driving innovation in APIs, formulations, biologics and NDDS.
Shilpa Medicare has been on a path of expansion ever since its inception in 1987. With a regulatory recognized manufacturing setup and excellent scientific expert team in place, Shilpa Medicare has been on a steady growth path for over three decades.
Currently, we are one of the leaders in the Oncology market and offer a complete range of products spanning across APIs, formulations, novel drug delivery systems, and biotech products.
Shilpa Antibiotics Ltd. established in Raichur, marking the beginning of Shilpa’s pharmaceutical journey.
Shilpa converted into a public company and listed on the Bombay Stock Exchange (BSE).
First patent filed, expansion of R&D capabilities, and recognition through multiple national export awards and ISO certifications.
Entry into oncology formulations with USFDA approvals for API and formulation facilities, first ANDA approvals, and EU Marketing Authorizations.
Strategic investments in biologics and novel drug delivery systems including oral thin films, transdermal systems, and specialty products.
Shilpa operates as an integrated global partner across APIs, formulations, oncology, and biologics with a growing CDMO focus.
The pharmaceutical industry is undergoing rapid transformation — driven by innovation, stricter regulatory frameworks and the growing need for affordability. At Shilpa, we see this as an opportunity to build sustainable value for patients, partners and shareholders.
Our strategy is to focus on difficult-to-make, high-value products, invest in world-class R&D and manufacturing, and strengthen our presence across APIs, formulations, oncology and biologics. We are committed to quality without compromise and affordability without shortcuts.
We are grateful to our employees, customers, partners and investors who have supported this journey. Together, we will continue to bring innovative, accessible healthcare solutions to patients across the world.
— Mr. Vishnukant Bhutada
Managing Director, Shilpa Medicare Limited
Across India, PCT and international markets including US, EU, Japan, Canada, Australia and New Zealand.
Specialized R&D sites in Raichur, Bangalore, Hubli and Ahmedabad.
Oncology, autoimmune disorders, diabetes, hematology and other complex conditions
cGMP manufacturing and robust quality systems across all facilities.
Innovation is part of Shilpa’s DNA. Every product we develop and every partnership we build is guided by our commitment to improving human health and making high-quality medicines more accessible.
Every product we develop, every patent we file, and every research initiative we undertake is driven by our commitment to improving human health and making a meaningful difference in patients' lives.
